Since his formative years, Mohosin Sarkar has been passionate about discovery research and science. He earned a bachelor’s degree in applied chemistry and chemical technology from the University of Dhaka in his home country of Bangladesh before immigrating to the United States in 2003. He continued his education at Kent State University, where he learned about patient treatment and therapeutic development, which piqued his interest and shifted his perspective on his career, leading to a Master of Science in biochemistry and molecular biology. He ultimately attained a PhD from Ohio State University in 2009, from which he was excited about the potential to change and improve patients’ lives.

Wielding degrees and credentials, Dr. Sarkar launched his career at the Scripps Research Institute, serving as a research associate and a senior researcher between 2010 and 2014. He then worked at Pfizer, where he was focused on therapeutic development in oncology and helped establish a novel therapeutic approach involving the crystallization of T cells for their activation. This included the use of biospecific carriers to activate TCR-engineered T cells specifically.

Since 2020, Dr. Sarkar has been active in leadership roles at EvolveImmune Therapeutics, a start-up company founded by two professors at Yale University, advancing from an associate director of antibody engineering to the director of biotherapeutics development. He manages a team of six there and contributes to patient solutions, building biotherapeutics from the ground up within its laboratory. He developed an innovative platform that integrates conventional and asymmetric methods, uniquely incorporating a molecule essential for T-cell activation and crystallization.

Over the course of his career, Dr. Sarkar—a longtime member of the American Association for Cancer Research and Society for Immunotherapy of Cancer—has accrued 11 patents at Scripps, Pfizer, and EvolveImmune. Looking toward the future, he strives to contribute significantly to the field by designing more effective drugs that improve patient outcomes, treat cancer, and help save lives.

His wife works as an analytical chemist at Johnson & Johnson, and his daughter attends Cornell University, where she is pursuing biomedical engineering.